PARN.F Stock Overview
A commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Parnell Pharmaceuticals Holdings Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.00% |
| 33 Year Change | -99.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PARN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | -99.0% | 14.2% | 32.3% |
Return vs Industry: PARN.F underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: PARN.F underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| PARN.F volatility | |
|---|---|
| PARN.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PARN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PARN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Brad McCarthy | www.parnell.com |
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection.
Parnell Pharmaceuticals Holdings Ltd Fundamentals Summary
| PARN.F fundamental statistics | |
|---|---|
| Market cap | US$120.00 |
| Earnings (TTM) | -US$922.47k |
| Revenue (TTM) | US$22.20m |
0.0x
P/S Ratio0.0x
P/E RatioIs PARN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PARN.F income statement (TTM) | |
|---|---|
| Revenue | AU$34.17m |
| Cost of Revenue | AU$14.90m |
| Gross Profit | AU$19.26m |
| Other Expenses | AU$20.68m |
| Earnings | -AU$1.42m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PARN.F perform over the long term?
See historical performance and comparison